Leah C. has extensive work experience in the pharmaceutical and healthcare industry. Leah is currently serving as a Senior QA Manager at Accession Therapeutics Limited since September 2022. Prior to their current role, Leah worked at Takeda as a GMP QA Program Manager from April 2020 to October 2022. Leah also held positions at GlaxoSmithKline KK as a Corporate Quality Assurance from February 2016 to June 2017, Otsuka Pharmaceuticals (UK) Ltd as an Interim PV/Compliance Manager from December 2013 to June 2014, Kosei Pharma as a Quality Assurance Manager/Qualified Person from May 2012 to March 2013, GE Healthcare as a Qualified Person from November 2003 to April 2011, Nycomed Amersham as a Quality Assurance Compliance Officer from July 1999 to November 2003, Amersham International as a Quality Control Microbiologist from May 1997 to July 1999, and Lonza Biologics as a Microbiologist from 1992 to 1997.
Leah C. attended Queen Mary University of London from 1989 to 1992, but their field of study was not specified. Leah also attended Brighton MET and Northbrook College from 2000 to 2002, where they focused on Industrial Pharmaceutical Sciences. No degree information was provided for either educational experience.
This person is not in any offices
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.